Neon joins the biotech IPO fiesta on Nasdaq, bagging $100M in the latest display of enthusiasm for drug developers
Neon Therapeutics just barely made it into the big H1 group of biotech IPOs that’s landed so far this year.
Hopes of helping open a new chapter in cancer therapy with their brand of highly personalized neoantigen vaccines — along with plenty of insider support — got them out of the gate on Nasdaq at $16 a share — landing in the middle of the range with a $100 million raise.
The biotech will start trading today as $NTGN.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.